ES2896056T3 - PD-ECGF como biomarcador de cáncer - Google Patents

PD-ECGF como biomarcador de cáncer Download PDF

Info

Publication number
ES2896056T3
ES2896056T3 ES16709410T ES16709410T ES2896056T3 ES 2896056 T3 ES2896056 T3 ES 2896056T3 ES 16709410 T ES16709410 T ES 16709410T ES 16709410 T ES16709410 T ES 16709410T ES 2896056 T3 ES2896056 T3 ES 2896056T3
Authority
ES
Spain
Prior art keywords
ecgf
sample
cancer
levels
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16709410T
Other languages
English (en)
Spanish (es)
Inventor
Casanovas Oriol Casanovas
Valerio Gabriela Jimenez
De Olza María Ochoa
Perez Valentí Navarro
Nicklas Bassani
Helena Verdaguer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut d'Investigació Biomédica de Bellvitge
Institut Català d'Oncologia
Original Assignee
Institut d'Investigació Biomédica de Bellvitge
Institut Català d'Oncologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia filed Critical Institut d'Investigació Biomédica de Bellvitge
Application granted granted Critical
Publication of ES2896056T3 publication Critical patent/ES2896056T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16709410T 2015-03-11 2016-03-10 PD-ECGF como biomarcador de cáncer Active ES2896056T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15382109.5A EP3067698A1 (en) 2015-03-11 2015-03-11 Pd-ecgf as biomarker of cancer
PCT/EP2016/055143 WO2016142471A1 (en) 2015-03-11 2016-03-10 Pd-ecgf as biomarker of cancer

Publications (1)

Publication Number Publication Date
ES2896056T3 true ES2896056T3 (es) 2022-02-23

Family

ID=52737037

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16709410T Active ES2896056T3 (es) 2015-03-11 2016-03-10 PD-ECGF como biomarcador de cáncer

Country Status (11)

Country Link
US (2) US11802874B2 (cg-RX-API-DMAC10.html)
EP (2) EP3067698A1 (cg-RX-API-DMAC10.html)
JP (3) JP2018512585A (cg-RX-API-DMAC10.html)
KR (1) KR102513020B1 (cg-RX-API-DMAC10.html)
CN (1) CN107667292B (cg-RX-API-DMAC10.html)
AU (1) AU2016231086B8 (cg-RX-API-DMAC10.html)
ES (1) ES2896056T3 (cg-RX-API-DMAC10.html)
HK (1) HK1250582A1 (cg-RX-API-DMAC10.html)
MX (1) MX384046B (cg-RX-API-DMAC10.html)
PL (1) PL3268744T3 (cg-RX-API-DMAC10.html)
WO (1) WO2016142471A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3740755B9 (en) * 2018-01-15 2023-10-04 Fundación Instituto de Investigación Sanitaria De Santiago de Compostela (FIDIS) Use of the tas1r3 protein as a marker for therapeutic, diagnostic, and/or prognostic purposes for tumors that express said protein
US12624695B2 (en) 2024-09-19 2026-05-12 Mahle International Gmbh Oil separator for compressor and compressor with oil separator

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3268147B2 (ja) * 1994-12-28 2002-03-25 大鵬薬品工業株式会社 モノクローナル抗体
WO2003086299A2 (en) 2002-04-09 2003-10-23 Government Of The United States Of America, Represnted By The Secretary, Department Of Health And Huuman Service Quantitative assay of the angiogenic and antiangiogenic activity of a test molecule
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌（ｒｃｃ）の潜在的な新規治療標的としての低酸素誘導タンパク質２（ｈｉｇ２）
EP1510588B1 (en) 2003-08-28 2007-01-31 Roche Diagnostics GmbH Correlation of the ratio of thymidine phosphorylase and dihydropyrimidine dehydrogenase mRNA expression levels in colorectal cancer with disease-free survival in 5-FU treated patients
WO2007115376A1 (en) 2006-04-11 2007-10-18 The University Of Western Australia Anti-angiogenic agents and methods of their use
US8642349B1 (en) * 2006-08-11 2014-02-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Artificial neural network proteomic tumor classification
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
IL313131A (en) * 2009-02-11 2024-07-01 Caris Mpi Inc Molecular characterization of tumors
US20120282631A1 (en) * 2009-03-20 2012-11-08 The Hong Kong Polytechnic University Method for diagnosis non-small-cell-lung-carcinoma (nsclc) and classification of its subtypes with different combinations of 6 protein biomarkers
US8110675B2 (en) 2009-06-15 2012-02-07 Chang Gung University TP expression-inhibiting compound and siRNA sequence thereof
US20100317029A1 (en) * 2009-06-15 2010-12-16 Lih-Chyang Chen Nasopharyngeal cancer malingancy biomarker and method thereof
CN101993919A (zh) * 2009-08-10 2011-03-30 芮屈生物技术（上海）有限公司 一种pd-ecgf基因的原位杂交检测试剂盒及其检测方法和应用
AU2011223789A1 (en) * 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
JP2014523398A (ja) 2011-03-23 2014-09-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 抗−インテグリンを用いた抗血管新生療法を改良するための方法及び組成物
CA2862835A1 (en) * 2012-01-13 2013-07-18 Genentech, Inc. Biological markers for identifying patients for treatment with vegf antagonists

Also Published As

Publication number Publication date
US12298307B2 (en) 2025-05-13
EP3268744B1 (en) 2021-08-11
JP2018512585A (ja) 2018-05-17
AU2016231086B8 (en) 2022-02-03
AU2016231086A1 (en) 2017-09-28
US11802874B2 (en) 2023-10-31
HK1250582A1 (zh) 2019-01-04
CA2978653A1 (en) 2016-09-15
CN107667292B (zh) 2020-06-19
WO2016142471A1 (en) 2016-09-15
AU2016231086B2 (en) 2021-08-12
US20240069029A1 (en) 2024-02-29
MX2017011467A (es) 2018-01-23
KR20170123638A (ko) 2017-11-08
EP3067698A1 (en) 2016-09-14
KR102513020B1 (ko) 2023-03-21
JP7453284B2 (ja) 2024-03-19
PL3268744T3 (pl) 2021-12-27
CN107667292A (zh) 2018-02-06
MX384046B (es) 2025-03-14
US20180052164A1 (en) 2018-02-22
JP2022153482A (ja) 2022-10-12
AU2016231086A8 (en) 2022-02-03
JP2020201278A (ja) 2020-12-17
EP3268744A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
Hudler et al. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics
Yi et al. Autoantibody to tumor antigen, alpha 2-HS glycoprotein: a novel biomarker of breast cancer screening and diagnosis
US20110053156A1 (en) Small cell lung carcinoma biomarker panel
CN103429757A (zh) 癌症诊断和治疗
US12298307B2 (en) PD-ECGF as biomarker of cancer
EP2270510A1 (en) Diagnostic method for predicting the risk of cancer recurrence based on Histone macroH2A isoforms
CA2830562A1 (en) Mucin 5b as a pancreatic cyst fluid specific biomarker for accurate diagnosis of mucinous cysts and other markers useful for detection of pancreatic malignancy
JP5403534B2 (ja) 食道癌の予後予測のための情報を提供する方法
TWI512294B (zh) 偵測致死系統之方法與組合物及其用途
JP2014513949A (ja) 患者における癌の診断方法
JP2003504073A (ja) Ｂａｇ発現のレベルを測定することによる、癌患者の予後を決定するための方法
JP5145549B2 (ja) 腫瘍マーカー
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
CA2978653C (en) Pd-ecgf as biomarker of cancer
AU2006290222A1 (en) Salivary protein and RNA for breast cancer detection
EP4650779A1 (en) Biomarker for diagnosis or prognosis of squamous cell lung carcinoma using exosomes and use thereof
EP2957913B1 (en) Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast
ES2743508T3 (es) Métodos y productos para el diagnóstico y el pronóstico de la malignidad de tumores de ovario
HK40026235A (en) Therapeutic treatment of breast cancer based on c-maf status